Abstract
The excessive contraction of small arteries under high blood pressure is the main contributor to the pathological change of hypertension. Current anti-hypertensive drugs, which lack a selective effect on small arteries in a hypertensive state, may cause many adverse effects. We have developed a novel opener of ATP-sensitive potassium channels, iptakalim, the vasorelaxing action of which is determined by the hypertensive status of small arteries. In conscious strokeprone, spontaneously hypertensive rats and “two-kidneys, one-clip” renal hypertensive dogs, this compound produced long-lasting hypotensive effects, with no tolerance. Furthermore, it exerted a protective effect against hypertensive damage to target organs. Given its potency and fewer side effects, iptakalim hydrochloride is a promising drug for the treatment of hypertension.
Keywords: hypertension, atp-sensitive potassium channel, iptakalim, small artery, vasodilator, side effects, selective hypotensive efficacy, cardiovascular remodeling
Current Vascular Pharmacology
Title: Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers
Volume: 3 Issue: 2
Author(s): Hai Wang, Ying-Li Zhang and Yu-Ping Chen
Affiliation:
Keywords: hypertension, atp-sensitive potassium channel, iptakalim, small artery, vasodilator, side effects, selective hypotensive efficacy, cardiovascular remodeling
Abstract: The excessive contraction of small arteries under high blood pressure is the main contributor to the pathological change of hypertension. Current anti-hypertensive drugs, which lack a selective effect on small arteries in a hypertensive state, may cause many adverse effects. We have developed a novel opener of ATP-sensitive potassium channels, iptakalim, the vasorelaxing action of which is determined by the hypertensive status of small arteries. In conscious strokeprone, spontaneously hypertensive rats and “two-kidneys, one-clip” renal hypertensive dogs, this compound produced long-lasting hypotensive effects, with no tolerance. Furthermore, it exerted a protective effect against hypertensive damage to target organs. Given its potency and fewer side effects, iptakalim hydrochloride is a promising drug for the treatment of hypertension.
Export Options
About this article
Cite this article as:
Wang Hai, Zhang Ying-Li and Chen Yu-Ping, Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers, Current Vascular Pharmacology 2005; 3 (2) . https://dx.doi.org/10.2174/1570161053586895
DOI https://dx.doi.org/10.2174/1570161053586895 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Current Drug Delivery Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Sleep and Antidepressant Treatment
Current Pharmaceutical Design The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews Ethyl Pyruvate: A Novel Treatment for Sepsis
Current Drug Targets Hepatotoxicity of Antiretroviral Drugs
Current Pharmaceutical Design Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
Current Medicinal Chemistry Adrenomedullin in Hypertension
Current Hypertension Reviews Syncope: Review of Monitoring Modalities
Current Cardiology Reviews Endotoxin Recognition Molecules MD-2 and Toll-like Receptor 4 as Potential Targets for Therapeutic Intervention of Endotoxin Shock
Current Drug Targets - Inflammation & Allergy Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets